Get the Stockscreener App
0.00
100.00%
-9.71
Fibrogen Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$9.71
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$39.28M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
0.00
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.00 | 39.28M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.83 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.98 | 79.20B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.84 | 50.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.73 | 47.29B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
337.14 | 37.55B | 4.98B | 69.59M | 525.67M | 0.5197 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
Quarterly Risk: Will FibroGen Inc benefit from AI trends2025 Retail Activity & Smart Allocation Stock Tips - baoquankhu1.vn
Price Action: Can FibroGen Inc be the next market leader2025 Trading Volume Trends & Fast Gain Swing Alerts - baoquankhu1.vn
Aug Technicals: Will FibroGen Inc stock benefit from M AWeekly Market Outlook & Community Trade Idea Sharing - baoquankhu1.vn
Jobs Data: Will FibroGen Inc. stock outperform international peers2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ
Sentiment Review: Will FibroGen Inc benefit from government policyMarket Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Aug Sentiment: Is FibroGen Inc. stock heavily shorted2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
RSI Check: Why FibroGen Inc stock remains on buy listsShort Setup & Reliable Intraday Trade Alerts - Bộ Nội Vụ
How FibroGen Inc. stock reacts to inflationary pressuresJuly 2025 Drop Watch & Risk Managed Investment Signals - Улправда
Trend Recap: Why FibroGen Inc. stock is a must watch in 2025Trade Signal Summary & Technical Confirmation Trade Alerts - ulpravda.ru
Why FibroGen Inc. stock is a must watch in 2025Market Growth Report & Fast Exit and Entry Trade Guides - Улправда
Aug Chart Watch: Is FibroGen Inc. stock undervalued vs historical averagesJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - Улправда
Published on: 2026-01-09 00:07:25 - Улправда
Is FibroGen Inc. stock a buy before product launches2025 Trading Recap & AI Based Trade Execution Alerts - Улправда
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - MarketScreener
FibroGen (FGEN) Faces Option Delistings as of January 8th - GuruFocus
One new option listing and one option delisting on January 8th - TipRanks
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB By Investing.com - Investing.com Nigeria
FibroGen nabs ex-Lilly Conterno as CEO - The Pharma Letter
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen stock rises after announcing rebrand to Kyntra Bio By Investing.com - Investing.com South Africa
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen rebrands to Kyntra Bio - marketscreener.com
Quarterly Earnings: Is FibroGen Inc stock a buy before product launchesJuly 2025 Review & Weekly Momentum Picks - moha.gov.vn
FibroGen shares advance after roxadustat earns orphan drug status - MSN
Published on: 2025-12-20 23:42:14 - Улправда
Why FibroGen Inc. (1FG0) stock attracts HNW investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
FibroGen Q3 2025 Earnings Preview - MSN
Published on: 2025-12-19 15:46:05 - Улправда
Will FibroGen Inc. stock outperform international peers2025 Market Trends & Safe Capital Preservation Plans - Улправда
Published on: 2025-12-18 12:26:14 - Улправда
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS By Investing.com - Investing.com Nigeria
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS - Investing.com India
FibroGen stock rises after roxadustat receives Orphan Drug Designation By Investing.com - Investing.com Nigeria
FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com India
FibroGen (FGEN) Gains FDA Orphan Drug Status for Roxadustat - GuruFocus
Roxadustat granted orphan drug designation for the treatment of myelodysplastic syndromes by the U.S. FDA - marketscreener.com
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
1.67%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):